<DOC>
	<DOCNO>NCT01949662</DOCNO>
	<brief_summary>The goal clinical research study learn give lorazepam combination haloperidol help control symptoms delirium patient advance cancer . The safety drug combination also study . In study , lorazepam compare placebo . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect .</brief_summary>
	<brief_title>Haloperidol Lorazepam Delirium Patients With Advanced Cancer</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group : - If Group 1 , receive lorazepam . - If Group 2 , receive placebo . Neither study staff know receive study drug placebo . However , need safety , study staff able find receiving . You equal chance group . All patient receive haloperidol part standard care . The study doctor tell haloperidol , design work , side effect may . Study Drug Administration : After start receive haloperidol , receive lorazepam placebo vein 1 time 1-2 minute . Study Tests : Every day palliative care unit , ask complete questionnaire symptom feel ask screening . If point recover confusion , ask remember confusion distress . Saliva Samples : While hospital , saliva sample ( 1/2 teaspoon ) collect every day check change body 's chemical level . To collect saliva , swab brush inside mouth enough saliva gather swab . This take 30 second complete . Length Study : You receive study drug placebo 1 time . You monitor part study leave palliative care unit . You may go study time you/your caregiver decide best interest . This investigational study . Lorazepam FDA approve commercially available treatment anxiety , insomnia , seizures . Its use help control agitation/delirium investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>1 . [ Patients ] Diagnosis advance cancer ( define locally advanced , metastatic , recurrent , incurable disease ) 2 . [ Patients ] Admitted Acute Palliative Care Unit ( APCU ) 3 . [ Patients ] Delirium per Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criteria 4 . [ Patients ] Hyperactive/mixed delirium RASS &gt; /=2 last 24 hour 5 . [ Patients ] On scheduled haloperidol &lt; /=8 mg last 24 hour 6 . [ Patients ] Age 18 old 7 . [ Patients ] Legally Authorized Representative consent 8 . [ Family Caregivers ] Patient 's spouse , adult child , sibling , parent , relative , significant ( defined patient partner ) 9 . [ Family Caregivers ] Age 18 old 10 . [ Family Caregivers ] At patient 's bedside least 4 hour day patient delirium episode 11 . [ Patients Family Caregivers ] Able communicate English Spanish 1 . [ Patients ] History myasthenia gravis acute narrow angle glaucoma 2 . [ Patients ] History neuroleptic malignant syndrome 3 . [ Patients ] History Parkinson 's disease dementia 4 . [ Patients ] Uncontrolled seizure disorder 5 . [ Patients ] History hypersensitivity haloperidol benzodiazepine 6 . [ Patients ] On regular dos benzodiazepine chlorpromazine within past 48 hour 7 . [ Patients ] Previously document persistent QTc prolongation ( &gt; 500 m ) 8 . [ Patients ] Heart failure exacerbation time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Locally advanced cancer</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Recurrent cancer</keyword>
	<keyword>Incurable cancer</keyword>
	<keyword>Delirium</keyword>
	<keyword>Agitation</keyword>
	<keyword>Lorazepam</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Placebo</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
	<keyword>Acute palliative care unit</keyword>
</DOC>